HK1250645A1 - 取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途 - Google Patents

取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途

Info

Publication number
HK1250645A1
HK1250645A1 HK18110118.6A HK18110118A HK1250645A1 HK 1250645 A1 HK1250645 A1 HK 1250645A1 HK 18110118 A HK18110118 A HK 18110118A HK 1250645 A1 HK1250645 A1 HK 1250645A1
Authority
HK
Hong Kong
Prior art keywords
dihydroimidazo
quinazolines
substituted
Prior art date
Application number
HK18110118.6A
Other languages
English (en)
Inventor
Ningshu Liu
Carol Pena
Michael Jeffers
Isabelle Genvresse
Original Assignee
Bayer Pharma AG
Bayer Healthcare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Healthcare Pharmaceuticals Inc filed Critical Bayer Pharma AG
Publication of HK1250645A1 publication Critical patent/HK1250645A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18110118.6A 2015-03-09 2018-08-07 取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途 HK1250645A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562130547P 2015-03-09 2015-03-09
PCT/EP2016/054728 WO2016142313A1 (en) 2015-03-09 2016-03-07 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Publications (1)

Publication Number Publication Date
HK1250645A1 true HK1250645A1 (zh) 2019-01-11

Family

ID=55484986

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110118.6A HK1250645A1 (zh) 2015-03-09 2018-08-07 取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途

Country Status (18)

Country Link
US (1) US20180042929A1 (zh)
EP (1) EP3268005A1 (zh)
JP (1) JP2018512403A (zh)
KR (1) KR20180013850A (zh)
CN (1) CN107683138A (zh)
AU (1) AU2016231260A1 (zh)
BR (1) BR112017019190A2 (zh)
CA (1) CA2978807A1 (zh)
CL (1) CL2017002284A1 (zh)
EA (1) EA201791975A1 (zh)
HK (1) HK1250645A1 (zh)
IL (1) IL254168A0 (zh)
MA (1) MA43840A (zh)
MX (1) MX2017011607A (zh)
PH (1) PH12017501644A1 (zh)
SG (1) SG11201707239WA (zh)
TN (1) TN2017000385A1 (zh)
WO (1) WO2016142313A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
MY192626A (en) 2013-04-08 2022-08-29 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3645005A1 (en) * 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
CN111500587A (zh) * 2020-04-15 2020-08-07 湖南省科域生物医药科技有限公司 Pgr作为治疗子宫内膜异位症的产品中的用途及其检测pgr的试剂盒
WO2021222895A1 (en) * 2020-05-01 2021-11-04 Mayo Foundation For Medical Education And Research Methods and materials for treating endometrial cancer
WO2022140467A1 (en) * 2020-12-21 2022-06-30 Samson Pharma, Llc Topical compositions and methods of treating skin diseases and conditions with such compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008003189A (es) * 2005-09-07 2008-03-18 Serono Lab Inhibidores de fosfoinositido 3-cinasa para el tratamiento de endometriosis.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2558126A2 (en) * 2010-04-16 2013-02-20 Bayer Intellectual Property GmbH Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
EP3003377A1 (en) * 2013-05-31 2016-04-13 Novartis AG Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer

Also Published As

Publication number Publication date
EA201791975A1 (ru) 2018-03-30
TN2017000385A1 (en) 2019-01-16
JP2018512403A (ja) 2018-05-17
CA2978807A1 (en) 2016-09-15
IL254168A0 (en) 2017-10-31
US20180042929A1 (en) 2018-02-15
EP3268005A1 (en) 2018-01-17
CL2017002284A1 (es) 2018-05-18
AU2016231260A1 (en) 2017-09-21
PH12017501644A1 (en) 2018-03-12
MA43840A (fr) 2018-11-21
KR20180013850A (ko) 2018-02-07
SG11201707239WA (en) 2017-10-30
WO2016142313A1 (en) 2016-09-15
CN107683138A (zh) 2018-02-09
MX2017011607A (es) 2018-04-10
BR112017019190A2 (pt) 2018-04-24

Similar Documents

Publication Publication Date Title
HK1250645A1 (zh) 取代的2，3-二氫咪唑並[1，2-c]喹唑啉類化合物的用途
HK1248231A1 (zh) 取代的喹唑啉化合物和其使用方法
IL254167A0 (en) Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline
HK1249758A1 (zh) 抗微生物化合物及其製備和使用方法
HK1245249A1 (zh) 二環喹唑啉酮衍生物
IL241543B (en) Use of converted 2, 3-dihydroimidazo[1, 2-c] quinazolines for the treatment of lymphoid tissue metastasis
IL253656A0 (en) Mono- and polyazanephthalene modified histories and their use
HRP20190013T1 (hr) Derivati 1,2-dihidro-3h-pirolo[1,2 -c]imidazol-3-ona i njihova uporaba kao antibakterijska sredstva
IL254476A0 (en) Heterocyclylmethyl-thianouracil as adenosine-a2b receptor antagonists
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
IL281274A (en) Methods for treating diuretic resistance
IL257413A (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
PT3135110T (pt) Derivados de 1,7-diaril-1,6-heptadieno-3,5-diona, processos para a produção e utilização dos mesmos
IL256488A (en) New bicyclic lipolantipeptide, preparation and use as antimicrobial agent
GB2575196B (en) Thieno pyridimine compounds and manufacture of the same
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
HK1244277A1 (zh) 新的取代的三唑並嘧啶作為抗瘧藥
ZA201801639B (en) Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials
TH1601002954A (th) ออกตะไฮโดร-ไซโคลบิวตะ[1,2-c;3,4-c']ไดไพร์โรล-2-อิล ใหม่